Moderna: launches study in seasonal influenza
(CercleFinance.com) - Moderna announces that the first participants have received a dose in a Phase III study of its seasonal influenza vaccine candidate (mRNA-1010), a trial that is expected to enroll approximately 6,000 adults in Southern Hemisphere countries.
This randomised, blinded, observer study is designed to assess the safety and immunological non-inferiority of mRNA-1010 compared to a licensed seasonal influenza vaccine in adults 18 years and older.
Starting in the fall of 2022, the company's Phase III pipeline could lead to three commercial launches in the respiratory sector over the next two to three years, Moderna said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.